march pandem forc pipelin delay
forma cash includ proce
februari transact includ up-front
payment close april well
end cash equival
kind gene therapi compani offer
intervent slowli progress diseas risk nosocomi
infect outweigh potenti benefit result
delay initi two clinic program slot
fabri diseas oncolog howev lead asset
phase studi advanc
rate umbrella progress schedul importantli recent
licens deal buy fein leav enviabl
balanc sheet cash weather delay furthermor
given modest ev littl beyond heavili discount
hem-a program bake stock near-term stock
remain leverag exemplifi drop week
follow data updat vs gain xbi driven
variabl fviii express new patient henc
choos give updat phase program
confirm differenti profil vs valrox biomarin
rate sangamo stock could come back vogu view
highlight corpor updat enrol continu
lead-in portion phase trial dose expect
commenc howev headwind could
impact patient schedul reason project current
manag guid follow-up phase alta
studi would suffici establish differenti vs
valrox especi patient maintain fviii activ
threshold hema program see updat view
 day initi staar trial
delay staar evalu one-and-don
base gene therapi fabri diseas staar trial current
recruit screen subject six site recent chang
screen criteria enhanc recruit patient
dose howev preliminari data unlik
narrow clinic lead vs competit program
addit pipelin updat patient dose ex-
vivo gene-edit treatment -thalassemia halt pend follow-
initi five patient data initi two patient present
underwhelm perch process enhanc
could posit impact magnitud durabl hb remain
valid patient enrol continu phase
studi evalu ex-vivo gene-edit
modal scd moa manag intend
updat program substanti
follow-up determin next step base current timelin
probabl cta treg cell therapi
renal transplant recipi clear dose
expect commenc
definit distribut analyst rate analyst certif disclosur pleas refer page report
housekeep oper loss vs estim ep line
estim sangamo exit quarter pro forma cash posit along anticip
develop mileston suffici fund oper least two year project
estim oper loss ep vs prior estim ep
valuat buy rate price target deriv risk-adjust sum-of-the-part analysi drive
dcf model dcf base beta termin growth rate risk premium calcul
wacc tax rate begin fy target primarili leverag repres
approxim rnpv per share recal progress entitl sangamo least
mileston payment along double-digit percentag world-wide royalti remain target reflect
contribut probability-adjust mileston payment rnpv current partnership sanofi
gilead rate unencumb fabri program rnpv sanofi-partn
rnpv remain assign develop scd note core vivo zfn
gene edit technolog recalibr rare genet diseas along implic ex vivo applic
cell current exclud rnpv base preclin statu risk could materi impair bullish
thesi includ reimburs regulatori clinic manufactur financ safeti unknown
durabl gene therapi gene edit could impact reimburs price note issu pertain public
percept gene therapi especi gene edit addit risk factor could neg impact commerci
adopt henc futur sale cash flow estim
discount tax non-cash work cash flow valu cash valu total per risk-fre rate yr premium equiti debt growth inc
thousand except per share data
net revenu research collabor
good sold
research develop
gener administr
interest incom expens net
total incom expens
loss incom tax
net loss attribut non-control interest
thousand except per share data
flow oper activ
amort discount market secur
gain free share
build-to-suit leas net loss leas termin
prepaid expens asset
account payabl accru liabil
accru compens employe benefit
long-term portion leas liabil
net cash provid use oper activ
flow invest activ
purchas properti equip invest
purchas matur market secur
acquisit net cash acquir
net cash provid use invest activ
flow financ activ
proce public offer common stock net issuanc cost
tax paid relat net share settlement equiti award
proce issuanc common stock
net cash provid use financ activ
effect chang foreign exchang rate
net increas decreas cash/cash equival
 equival begin period
 equival end period
thousand except per share data
cash equival
prepaid expens current asset
properti equip net
liabil stockhold equiti
account payabl accru liabil
accru compens employe benefit
long-term portion leas liabil build-to-suit leas oblig
accumul comprehens loss
total liabil stockhold equiti
outlook ratio analysi enterpris valu
burn period cash oper
total cash cash equival interest receiv
period cash remain
ebitda sale
return asset roa
return equiti roe
materi confidenti intend use institut account defin finra rule may also
privileg otherwis protect work product immun legal rule receiv mistak pleas let
us know email repli delet system may copi messag
disclos content anyon integr secur messag guarante internet
 wainwright co llc rate wainwright employ three tier rate system evalu
potenti return risk associ own common equiti share rate firm expect return given
equiti measur rel basi compani sector price object calcul estim
potenti movement price given equiti could reach provid certain target met defin time horizon
price object subject extern factor includ industri event market volatil
market outperform buy common stock compani expect outperform passiv index compris
common stock compani within sector
market perform neutral common stock compani expect mimic perform passiv index
compris common stock compani within sector
market under-perform sell common stock compani expect under-perform passiv index compris
common stock compani within sector
rate price target histori inc sgmo-u
rate price target histori inc biib-u
relat compani mention report
invest bank servic includ limit act manager/co-manag underwrit placement
secur act financi advisor and/or provid corpor financ capit markets-rel servic compani
one affili subsidiari within past month
distribut rate tabl may
 wainwright co llc firm member finra sipc regist broker-deal
debjit chattopadhyay earl desouza certifi view express report accur reflect person
view subject secur issuer discuss part compens directli
indirectli relat specif recommend view express research report neither
member household offic director advisori board member compani
none research analyst research analyst household financi interest secur sangamo
therapeut inc inc includ without limit option right warrant futur long short posit
april neither firm affili benefici class common equiti secur
inc inc
neither research analyst firm know reason know materi conflict interest time
public research report
research analyst princip respons prepar report receiv compens base upon
specif invest bank servic transact compens base factor includ total revenu profit
firm substanti portion deriv invest bank servic
firm affili receiv compens inc inc invest bank
servic within twelv month seek compens compani mention report invest
bank servic within three month follow public research report
firm make market sangamo inc inc date research report
secur compani discuss report may unsuit investor depend specif invest
object financi posit past perform guarante futur result report offer inform
purpos constitut offer solicit buy sell secur discuss herein jurisdict
would prohibit research report intend provid tax advic use provid tax advic
person electron version wainwright co llc research report made avail client simultan
part report may reproduc form without express permiss wainwright co llc addit
 wainwright co llc provid individu tailor invest advic research report research report
intend provid person invest advic take account specif invest object financi
situat particular need specif person investor seek financi advic regard appropri
invest financi instrument implement invest strategi discuss recommend research report
 wainwright co llc affili salespeopl trader profession may provid oral written market
commentari trade strategi reflect opinion contrari opinion express research report
 wainwright co llc affili offic director employe exclud analyst time time
long short posit act princip buy sell secur deriv includ option warrant
thereof cover compani refer research report
inform contain herein base sourc believ reliabl guarante us
accur purport complet statement summari avail data compani industri secur
discuss report opinion estim includ report constitut analyst judgment date
report subject chang without notic
secur financi instrument discuss research report may lose valu insur feder
deposit insur corpor subject invest risk includ possibl loss princip amount invest
